Phase 1b/2 Study of HCW9218 for Advanced Pancreatic Cancer
Status:
Not yet recruiting
Trial end date:
2023-04-01
Target enrollment:
Participant gender:
Summary
This is a Phase 1b/2, open-label, multi-center, competitive enrollment and dose-escalation
study of HCW9218 in patients with advanced/metastatic pancreatic cancer.